---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-058228"
form_type: "8-K"
ticker: "DERM"
cik: "0001867066"
company_name: "Journey Medical Corp"
filed_at: "2022-05-10T23:59:59+00:00"
generated_at: "2026-06-25T22:01:30.852715+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Journey Medical reports record Q1 revenue of $23.3M, up 117% YoY; net loss of $1.4M

## Summary
- Record net product revenue $20.8M (+94% YoY); $2.5M milestone from Maruho for QBREXZA Japan approval.
- Net loss of $1.4M ($0.08/share) vs net income $0.3M ($0.03) in Q1 2021; adjusted EBITDA $2.3M vs $1.2M.
- First patient dosed in Phase 3 trial for DFD-29 for papulopustular rosacea; one additional product launch planned in H2 2022.
- Expanded product portfolio with Amzeeq and Zilxi launches; now 9 marketed prescription dermatology products.

## SEC filing metadata
- accession: 0001104659-22-058228
- form_type: 8-K
- ticker: DERM
- cik: 0001867066
- company_name: Journey Medical Corp
- filed_at: 2022-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867066/000110465922058228/0001104659-22-058228-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867066/000110465922058228/tm2214972d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-058228
- JSON: https://secwatch.observer/filing/0001104659-22-058228.json
- Plain text: https://secwatch.observer/filing/0001104659-22-058228.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.